Skip to main content
. 2021 Jun 7;11(6):1048. doi: 10.3390/diagnostics11061048

Figure 4.

Figure 4

ART differentiates between benign and malignant disease in ascites fluid from ovarian cancer patients. (A) Total and (B) active CXCL10 concentrations measured in benign (n = 51) and malignant (n = 212) ascites fluid samples. (C,D) Calculated active ratio between (C) benign and all malignant samples; or (D) benign and cancer samples separated according to FIGO disease stage. **** p ≤ 0.0001.